Serum caffeine concentrations and short-term outcomes in premature infants of ≤29 weeks of gestation

Journal of Perinatology

Volumn 35, Issue 6, 2015, Pages 434-438

  Alur, P ^a   Bollampalli, V ^a   Bell, T ^a   Hussain, N ^b   Liss, J ^a  

^a YORK HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; ASIAN; BLOOD LEVEL; BRAIN HEMORRHAGE; CAUCASIAN; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DURATION OF VENTILATION; FEMALE; HISPANIC; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; OXYGEN AT DISCHARGE; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; BLOOD; CHRONIC DISEASE; GESTATIONAL AGE; HOSPITAL CHARGE; LUNG DISEASES; LUNG INJURY;

CAFFEINE; CHRONIC DISEASE; GESTATIONAL AGE; HOSPITAL CHARGES; HUMANS; INFANT, PREMATURE; LENGTH OF STAY; LUNG DISEASES; LUNG INJURY; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84929960468     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2014.226     Document Type: Article

References (36)

1. Jacobson KA. Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol 2009; (193): 1-24; PMCID: PMC3415694.
2. Rivkees SA, Zhao Z, Porter G, Turner C. Influences of adenosine on the fetusand newborn. Mol Genet Metab 2001; 74(1-2): 160-171.
3. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354(20): 2112-2121.
4. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Longterm effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357(19): 1893-1902.
5. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: An unnecessary exercise? Pediatrics 2007; 119(5): 936-940.
6. Chavez Valdez R, Ahlawat R, Wills-Karp M, Nathan A, Ezell T, Gauda EB. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr 2011; 158(1): 57-64, 64 e51.
7. Du Y, Melchert HU, Knopf H, Braemer-Hauth M, Pabel E. Association of serum caffeine concentrations with serum glucose levels in caffeine-drug users and nonusers-results of German National Health Surveys. Diabetes Obes Metab 2007; 9(5): 756-758.
8. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 2012; 30(3): 559-572.
9. Tiwari KK, Chu C, Couroucli X, Moorthy B, Lingappan K. Differential concentrationspecific effects of caffeine on cell viability, oxidative stress, and cell cycle in pulmonary oxygen toxicity in vitro. Biochem Biophys Res Commun 2014; 450(4): 1345-1350.
10. Banerjee P, Ali Z, Levine B, Fowler DR. Fatal caffeine intoxication: A series of eight cases from 1999 to 2009. J Forensic Sci 2014; 59(3): 865-868.
11. al-Alaiyan S, al-Rawithi S, Raines D, Yusuf A, Legayada E, Shoukri MM et al. Caffeine metabolism in premature infants. J Clin Pharmacol 2001; 41(6): 620-627.
12. Aranda JV, Collinge JM, Zinman R, Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child 1979; 54(12): 946-949.
13. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 1979; 95(5 Pt 2): 819-823.
14. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92(4): 529-534.
15. DeReuck J, Chattha AS, Richardson EP Jr. Pathogenesis and evolution of periventricular leukomalacia in infancy. Arch Neurol 1972; 27(3): 229-236.
16. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187(1): 1-7.
17. Patz A. New international classification of retinopathy of prematurity. Pediatrics 1984; 74(8): 160-161.
18. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med 2010; 23(Suppl 3): 20-23.
19. Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr 2014; 164(5): 992-998.
20. Schmidt B, Davis PG, Roberts RS. Timing of caffeine therapy in very low birth weight infants. J Pediatr 2014; 164(5): 957-958.
21. Li J, Li G, Hu JL, Fu XH, Zeng YJ, Zhou YG et al. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. Eur J Pharmacol 2011; 654(3): 295-303.
22. Miller JL, Nandyal RR, Anderson MP, Escobedo MB. Relationship of caffeine dosing with serum alkaline phosphatase levels in extremely low-birth-weight infants. J Pediatr Pharmacol Ther 2012; 17(1): 58-66.
23. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M et al. PBPK modelling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health Part A 2004; 67(4): 297-329.
24. Cazeneuve C, Pons G, Rey E, Treluyer JM, Cresteil T, Thiroux G et al. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol 1994; 37(5): 405-412.
25. Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics 2012; 5(5): 389-395.
26. Leon AE, Michienzi K, Ma CX, Hutchison AA. Serum caffeine concentrations in preterm neonates. Am J Perinatol 2007; 24(1): 39-47.
27. Patel RM, Leong T, Carlton DP, Vyas-Read S. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol 2013; 33(2): 134-140.
28. Chavez-Valdez R, Wills-Karp M, Ahlawat R, Cristofalo EA, Nathan A, Gauda EB. Caffeine modulates TNF-alpha production by cord blood monocytes: The role of adenosine receptors. Pediatr Res 2009; 65(2): 203-208.
29. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008; 111(4): 2024-2035.
30. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005; 5(9): 712-721.
31. Crossley KJ, Allison BJ, Polglase G, Morley CJ, Harding R, Davis PG et al. Effects of caffeine on renal and pulmonary function in preterm newborn lambs. Pediatr Res 2012; 72: 19-25.
32. Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants. Eur J Pediatr 2009; 168(12): 1491-1495.
33. Rivkees SA, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011; 69(4): 271-278.
34. Clyman RI, Roman C. The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Res 2007; 62(2): 167-169.
35. Geraets L, Moonen HJ, Wouters EF, Bast A, Hageman GJ. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem Pharmacol 2006; 72(7): 902-910.
36. Micallef S, Amzal B, Bach V, Chardon K, Tourneux P, Bois FY. Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates. Clin Pharmacokinet 2007; 46(1): 59-74.